Современный взгляд на лечение гигантоклеточной опухоли кости в эру деносумаба. Обзор литературы
https://doi.org/10.17650/2070-9781-2020-12-4-11-21
Аннотация
В статье представлен обзор мировой литературы на тему лечения гигантоклеточной опухоли кости с учетом сверх-экспрессии RANKL и основанного на этом применения деносумаба. Рассмотрены аспекты патогенеза гигантоклеточной опухоли на основе открытого в 1990-х годах процесса остеокластогенеза (RANK/RANKL) и новой драйвер-мутации H3F3A. Представлены история, опыт и результаты применения деносумаба, а также проблемы оценки и интерпретации эффекта лечения.
Ключевые слова
гигантоклеточная опухоль,
деносумаб,
опухоль кости,
RANKL,
RANK,
местный рецидив,
злокачественная трансформация,
H3F3A,
G34W,
оценка эффекта
Об авторах
А. А. Тарарыкова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
А. А. Феденко
ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России
Россия
Россия
125284 Москва, 2-й Боткинский проезд, 3
Э. Р. Мусаев
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России
Россия
Россия
115478 Москва, Каширское шоссе, 24
Список литературы
1. Larsson S.E., Lorentzon R., Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968. J Bone Joint Surg Am 1975;57(2):167−73.
2. Baena-Ocampo L., Del C., Ramirez-Perez E. et al. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol 2009;13(1):16−21. DOI: 10.1016/j.anndiagpath.2008.07.005.
3. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 2006;30(6):484−9. DOI: 10.1007/s00264-006-0215-7.
4. Viswanathan S., Jambhekar N.A. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res 2010;468(3):827−33. DOI: 10.1007/s11999-009-0966-8.
5. Charest-Morin R., Fisher C.G., Varga P.P. et al. En Bloc Resection Versus Intralesional Surgery in the Treatment of Giant Cell Tumor of the Spine. Spine (Phila Pa 1976) 2017;42(18):1383−90. DOI: 10.1097/BRS.0000000000002094.
6. Rendina D., Mossetti G., Soscia E. et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004;(421):218−24. DOI: 10.1097/00000118702.46373.e3.
7. Kim G.S., Kim S.H., Cho J.K. et al. Paget bone disease involving young adults in 3 generations of a Korean family. Medicine (Baltimore) 1997;76(3):157−69.
8. Cohen M.M.Jr., Gorlin R.J. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet 1991;40(2):159–66. DOI: 10.1002/ajmg.1320400208.
9. Sinnott B.P., Patel M. Giant cell lesion of the jaw as a presenting feature of Noonan syndrome. BMJ Case Rep 2018;2018. DOI: 10.1136/bcr-2017-224115.
10. van den Berg H., Schreuder W.H., Jongmans M. et al. Multiple giant cell lesions in a patient with Noonan syndrome with multiple lentigines. Eur J Med Genet 2016;59(8):425−8. DOI: 10.1016/j.ejmg.2016.05.013.
11. Karbach J., Coerdt W., Wagner W., Bartsch O. Case report: Noonan syndrome with multiple giant cell lesions and review of the literature. Am J Med Genet A 2012;158A(9):2283−9. DOI: 10.1002/ajmg.a.35493.
12. Balke M., Ahrens H., Streitbuerger A. et al. Treatment options for recurrent giant cell tumours of bone. J Cancer Res Clin Oncol 2009;135(1):149–58.
13. Yang Y., Huang Z., Niu X. et al. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol 2017;7:23−8.
14. Flanagan A.M., Larousserie F. et al. Giant Cell Tumour of Bone. In: WHO Classification of Tumours of Soft Tissue and Bone, 5th ed., IARC, Geneva 2020. P. 440.
15. Amelio J.M., Rockberg J., Hernandez R.K. et al. Population-based study of giant cell tumor of bone in Sweden (1983−2011). Cancer Epidemiol 2016;42:82−9. DOI: 10.1016/j.canep.2016.03.014.
16. Bertoni F., Bacchini P., Staals E.L. Malignancy in giant cell tumor of bone. Cancer 2003;97(10):2520−9. DOI: 10.1002/cncr.11359.
17. Rock M.G., Sim F.H., Unni K.K. et al. Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am 1986;68(7):1073−9.
18. Sato K., Yamamura S., Iwata H. et al. Giant cell-rich osteosarcoma: a case report. Nagoya J Med Sci 1996;59(3−4):151−7.
19. Domovitov S.V., Healey J.H. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol 2010;17(3):694−701. DOI: 10.1245/s10434-009-0803-z.
20. Anract P., De Pinieux G., Cottias P. et al. Malignant giant-cell tumours of bone. Clinicopathological types and prognosis: a review of 29 cases. Int Orthop 1998;22(1):19−26. DOI: 10.1007/s002640050201.
21. Atkins G.J., Haynes D.R., Graves S.E. et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000;15(4):640−9. DOI: 10.1359/jbmr.2000.15.4.640.
22. Atkins G.J., Kostakis P., Vincent C. et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006;21(9):1339−49. DOI: 10.1359/jbmr.060604.
23. Lau Y.S., Sabokbar A., Gibbons C.L. et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36(9):945−54. DOI: 10.1016/j.humpath.2005.07.005.
24. Morgan T., Atkins G.J., Trivett M.K. et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005;167(1):117−28. DOI: 10.1016/s0002-9440(10)62959-8.
25. Liao T.S., Yurgelun M.B., Chang S.S. et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005;23(1):203−9.DOI: 10.1016/j.orthres.2004.06.018.
26. Anazawa U., Hanaoka H., Shiraishi T. et al. Similarities between giant cell tumor of bone, giant cell tumor of tendon sheath, and pigmented villonodular synovitis concerning ultrastructural cytochemical features of multinucleated giant cells and mononuclear stromal cells. Ultrastruct Pathol 2006;30(3):151−8.
27. Dougall W.C., Glaccum M., Charrier K. et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13(18):2412−24. DOI: 10.1101/gad.13.18.2412.
28. Kim N., Odgren P.R., Kim D.K. et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte- expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97(20):10905−10. DOI: 10.1073/pnas.200294797.
29. Simonet W.S., Lacey D.L., Dunstan C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309−19. DOI: 10.1016/s0092-8674(00)80209-3.
30. Ng P.K., Tsui S.K., Lau C.P. et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 2010;110(2):438−46. DOI: 10.1002/jcb.22556.
31. Skubitz K.M., Cheng E.Y., Clohisy D.R. et al. Gene expression in giant-cell tumors. J Lab Clin Med 2004;144(4):193−200. DOI: 10.1016/j.lab.2004.06.005.
32. Huang L., Xu J., Wood D.J., Zheng M.H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell- induced osteoclast-like cell formation. Am J Pathol 2000;156(3):761−7. DOI: 10.1016/s0002-9440(10)64942-5.
33. Ahmed A.A., Dunlap C. Immunohistochemical detection of the receptor activator of nuclear factor Kappa B ligand and c-fos in giant cell granuloma. J Oral Maxillofac Pathol 2016;20(1):47−50. DOI: 10.4103/0973-029X.180928.
34. Lindeman J.H., Hanemaaijer R., Mulder A. et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165(2):593−600. DOI: 10.1016/S0002-9440(10)63323-8.
35. Mak I.W., Seidlitz E.P., Cowan R.W. et al. Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone. Hum Pathol 2010;41(9):1320−9. DOI: 10.1016/j.humpath.2010.03.001.
36. Hanna N., Parfait B., Talaat I.M. et al. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Clin Genet 2009;75(6):568−71. DOI: 10.1111/j.1399-0004.2009.01149.x.
37. Malawer M., Helman L., O’Sullivan B. Giant cell tumour of the bone. In: DeVita V., Lawrence T., Rosenberg S., eds. Principles and Practice of Oncology, 8th edn. Philadelphia: Lippincott, Williams and Wilkins, 2008.
38. Carapito R., Paul N., Untrau M. et al. A new mutation in the C-SH2 domain of PTPN11causes Noonan syndrome with multiple giant cell lesions. J Hum Genet 2014;59(1):57−9. DOI: 10.1038/jhg.2013.118.
39. Behjati S., Tarpey P.S., Presneau N. et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45:1479–82. DOI: 10.1038/ng.2814 30.
40. Amary F., Berisha F., Ye H. et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol 2017;41:1059–68. DOI: 10.1097/PAS.0000000000000859.
41. Nohr E., Lee L.H., Cates J.M. et al. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors. Hum Pathol 2017;68:119–27. DOI: 10.1016/j.humpath.2017.08.030 32.
42. Yamamoto H., Iwasaki T., Yamada Y. et al. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol 2018;73:41–50. DOI: 10.1016/j.humpath.2017.11.020.
43. Lüke J., von Baer A., Schreiber J. et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology 2017;71(1):125−33. DOI: 10.1111/his.13190.
44. Presneau N., Baumhoer D., Behjati S. et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res 2015;1(2):113−23. DOI: 10.1002/cjp2.13
45. Felleberg J., Sahr H., Mancarella D. et al. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. Cancer Lett 2019;448:61–9. DOI: 10.1016/j.canlet.2019.02.001.
46. Noh B.J., Park Y.K. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. Hum Pathol 2018;81:1−8. DOI: 10.1016/j.humpath.2018.06.017.
47. Palmerini E., Chawla N.S., Ferrari S. et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Eur J Cancer 2017;76:118−24. DOI: 10.1016/j.ejca.2017.01.028.
48. Thomas D.M. RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol 2012;24(4):397–403. DOI: 10.1097/cco.0b013e328354c129.
49. Cummings S.R., San Martin J., McClung M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65. DOI: 10.1056/NEJMoa0809493.
50. Rifkin W.D. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:2390–91.
51. Smith M.R., Egerdie B., Hernandez Toriz N. et al. Denosumab in men receiving androgendeprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55. DOI: 10.1056/NEJMoa0809003.
52. Henry D.H., Costa L., Goldwasser F. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–32. DOI: 10.1200/JCO.2010.31.3304.
53. Thomas D., Henshaw R., Skubitz K. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11(3):275−80. DOI: 10.1016/S1470-2045(10)70010-3.
54. Ueda T., Morioka H., Nishida Y. et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol 2015;26(10):2149−54. DOI: 10.1093/annonc/mdv307.
55. Chawla S., Blay J.Y., Rutkowski P. et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 2019;20(12):1719−29. DOI: 10.1016/S1470-2045(19)30663-1.
56. Lipton A., Saad F., Van Poznak C.H. et al. Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials. J Clin Oncol 2013;31S:ASCO#9640.
57. Li H., Gao J., Gao Y. et al. Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls. Front Oncol 2020;10:580605. DOI: 10.3389/fonc.2020.580605.
58. Rutkowski P., Ferrari S., Grimer R.J. et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015;22(9):2860−8. DOI: 10.1245/s10434-015-4634-9.
59. Broehm C.J., Garbrecht E.L., Wood J., Bocklage T. Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab. Case Rep Med 2015;2015:767198. DOI: 10.1155/2015/767198.
60. Aponte-Tinao L.A., Piuzzi N.S., Roitman P., Farfalli G.L. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab. Clin Orthop Relat Res 2015;473(9):3050−5. DOI: 10.1007/s11999-015-4249-2.
61. Park A., Cipriano C.A., Hill K. et al. Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report. JBJS Case Connect 2016;6:e78.
62. Tsukamoto S., Mavrogenis A.F., Tanzi P. et al. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation. J Surg Oncol 2019;119(7):864−72. DOI: 10.1002/jso.25391.
63. Agarwal M.G., Gundavda M.K., Gupta R., Reddy R. Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience. Clin Orthop Relat Res 2018;476:1773–82. DOI: 10.1007/s11999.0000000000000243.
64. Chen Z., Yang Y., Guo W. et al. Therapeutic benefits of neoadjuvant and post-operative denosumab on sacral giant cell tumor: a retrospective cohort study of 30 cases. J Buon 2018;23(2):453–9.
65. Tsukamoto S., Righi A., Vanel D. et al. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol 2017; 47(11):1090−96. DOI: 10.1093/jjco/hyx112.
66. Ferrari-Lacraz S., Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 2011;22:435–46. DOI: 10.1007/s00198-010-1326-y.
67. Kong Y.Y., Yoshida H., Sarosi I. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315–23. DOI: 10.1038/16852.
68. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55. DOI: 10.1056/NEJMoa0809003.
69. Mori K., Berreur M., Blanchard F. et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 2007;18:1365–71. DOI: 10.3892/or.18.6.1365.
70. Becker-Santos D.D., Lonergan K.M., Gronostajski R.M., Lam W.L. Nuclear factor I/B: a master regulator of cell differentiation with paradoxical roles in cancer. EBioMedicine 2017;22:2–9. DOI: 10.1016/j.ebiom.2017.05.027.
71. Hayashi M., Nakashima T., Taniguchi M. et al. Osteoprotection by semaphorin 3A. Nature 2012;485:69–74. DOI: 10.1038/nature11000.
72. Behar O., Golden J.A., Mashimo H. et al. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 1996;383:525–8. DOI: 10.1038/383525a0.
73. Mak I.W., Evaniew N., Popovic S. et al. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 2014;96:e127. DOI: 10.2106/JBJS.M. 01332.
74. Matcuk G.R.Jr., Patel D.B., Schein A.J. et al. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skeletal Radiol 2015;44:1027–31. DOI: 10.1007/s00256-015-2117-5.
75. Luengo-Alonso G., Mellado-Romero M., Shemesh S. et al. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg 2019;139(10):1339−49. DOI: 10.1007/s00402-019-03167-x.
76. Wojcik J., Rosenberg A.E., Bredella M.A. et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol 2016;40:72–80. DOI: 10.1097/PAS.0000000000000506.
77. Roitman P.D., Jauk F., Farfalli G.L. et al. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls. Hum Pathol 2017;63:89–97. DOI: 10.1016/j.humpath.2017.02.008.
78. Santosh N., Mayerson J.L., Iwenofu O.H. Pseudosarcomatous spindle cell proliferation with osteoid matrix mimicking osteosarcoma: a distinct histologic phenotype in giant cell tumor of bone following denosumab therapy. Appl Immunohistochem Mol Morphol 2016;24:e18–9. DOI: 10.1097/PAI.0000000000000165.
79. Sanchez-Pareja A., Larousserie F., Boudabbous S. et al. Giant cell tumor of bone with pseudosarcomatous changes leading to premature denosumab therapy interruption: a case report with review of the literature. Int J Surg Pathol 2016;24(4):366–72. DOI: 10.1177/1066896916629546.
80. Charles J.F., Aliprantis A.O. Osteoclasts: more than ’bone eaters’. Trends Mol Med 2014;20:449–59. DOI: 10.1016/j.molmed.2014.06.001.
81. Kubota K., Sakikawa C., Katsumata M. et al. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 2002;17:257–65. DOI: 10.1359/jbmr.2002.17.2.257.
82. Traub F., Singh J., Dickson B.C. et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer 2016;59:1−12. DOI: 10.1016/j.ejca.2016.01.006.
83. Boye K., Jebsen N.L., Zaikova O. et al Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. Acta Oncol 2017;56(3):479. DOI: 10.1080/0284186X.2016.1278305.
Рецензия
Для цитирования:
Тарарыкова А.А., Феденко А.А., Мусаев Э.Р. Современный взгляд на лечение гигантоклеточной опухоли кости в эру деносумаба. Обзор литературы. Саркомы костей, мягких тканей и опухоли кожи. 2020;12(4):11-21. https://doi.org/10.17650/2070-9781-2020-12-4-11-21
For citation:
Tararykova A.A., Fedenko A.A., Musaev E.R. Management of giant cell tumor in the denosumab era. Literature review. Bone and soft tissue sarcomas, tumors of the skin. 2020;12(4):11-21. (In Russ.) https://doi.org/10.17650/2070-9781-2020-12-4-11-21
Просмотров:
499
Послать статью по эл. почте 
